Thermo Fisher to Acquire Clario Holdings, Enhancing Clinical Trial Insight

Thermo Fisher Scientific has entered into a definitive agreement to acquire Clario Holdings, Inc., a leader in endpoint data solutions for clinical trials, in a transaction valuing Clario at approximately US$8.9 billion in cash, with additional performance-based payments possible. The acquisition is expected to close by mid-2026, subject to regulatory approvals and customary closing conditions.

Clario’s platform collects and analyzes clinical trial data from devices, sites and patients thereby enabling sponsors to derive deeper insights and make faster decisions.  Thermo Fisher says the move will strengthen its offerings for pharmaceutical and biotech customers seeking to accelerate drug development and bring therapies to patients more efficiently. 

In financial terms the deal is expected to be immediately accretive to adjusted earnings per share and generate meaningful operating synergies over time. By integrating Clario’s capabilities, Thermo Fisher aims to expand its digital and data-driven services in the clinical research space, aligning with growing demand for smarter, technology-enabled trials.